Communiqués Pasithea Therapeutics Corp.

Actions

KTTA

US70261F2020

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:33:03 31/08/2026			Varia. 5j.	Varia. 1 janv.
0,5760 ^USD	+2,86%		+11,88%	-56,20%

14/08	Pasithea Therapeutics Corp. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
30/06	Pasithea Therapeutics publie des données intérimaires positives pour son étude de phase 1 sur le cancer avancé et annonce une extension du protocole	CI

Communiqués

21/07	Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026	AQ
08/07	Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit	AQ
30/06	Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion	AQ
16/06	Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial	AQ
15/06	Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference	AQ
02/06	Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)	AQ
06/05	Pasithea Therapeutics : Initial Statement of Beneficial Ownership (Form 3)	PU
04/05	Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer	AQ
20/04	Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)	AQ
02/04	Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity	AQ
01/04	Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity	AQ
17/02	Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
13/01	Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines	AQ
12/01	Pasithea Therapeutics : Investor Presentation	PU
02/12	Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock	AQ
01/12	Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock	AQ
28/11	Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock	AQ
25/11	Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS	AQ
25/11	Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic, and Pharmacodynamic Data	AQ
25/11	Pasithea Therapeutics : Investor Presentation	PU
24/11	Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data	AQ
21/11	Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients	AQ
21/11	Pasithea Therapeutics : Investor Presentation	PU
20/11	Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study	AQ
04/11	Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients	AQ